NCT06718127 Description of the Immune Response to Yellow Fever Vaccination
| NCT ID | NCT06718127 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut Pasteur |
| Condition | Immunization |
| Study Type | INTERVENTIONAL |
| Enrollment | 38 participants |
| Start Date | 2024-09-30 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 38 participants in total. It began in 2024-09-30 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Vaccine protection depends on a specific adaptive immune memory. However, a little-explored aspect of certain live vaccines may provide beneficial, non-specific protection against infections or pathogens other than the one from which the vaccine is derived. This is the concept of innate immune memory or " trained immunity", which differs from adaptive memory in its non-specificity. Innate immune memory is triggered by exposure to immunostimulants, and offers protection against unrelated pathogenic threats for several months or even years. The project aims to carry out an exploratory study to observe, in the context of current practice, the immune response obtained after a subunit and a live attenuated vaccine
Eligibility Criteria
Inclusion Criteria: * Age between 18 and 65 * Referred for immunisation against yellow fever and typhoid * Any person with indication for the following vaccinations : * Yellow fever * Typhoïd * Whose vaccination schedule includes two appointments 7 days apart * Whose state of health is compatible with a single 51 ml blood sample collection * Have consented to participate in the Ivory2 study * Benefiting from a Social Security plan or equivalent Exclusion Criteria: * Anyone with a contraindication to yellow fever and/or typhoid vaccination. * Any person who has been vaccinated against yellow fever and/or typhoid. * Anyone who has lived in an endemic area (≥ 1 year) and/or has a history of Typhoid. * Anyone who is unable to attend the visit 1-month after the typhoid vaccine injection. * Women claiming to be pregnant or breast-feeding * Anyone unable to give informed consent for participation
Contact & Investigator
Fabien Taieb, Dr
PRINCIPAL INVESTIGATOR
Institut Pasteur
Frequently Asked Questions
Who can join the NCT06718127 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Immunization. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06718127 currently recruiting?
Yes, NCT06718127 is actively recruiting participants. Contact the research team at jessica.quintin@pasteur.fr for enrollment information.
Where is the NCT06718127 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT06718127 clinical trial?
NCT06718127 is sponsored by Institut Pasteur. The principal investigator is Fabien Taieb, Dr at Institut Pasteur. The trial plans to enroll 38 participants.